Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutazumab in adults with type 2 diabetes mellitus
ACTRN12617000811303Phase 2Recruiting
- Sponsor
- Gmax Biopharm
- Start
- Oct 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Glutazumab with Placebo (2 arms). Primary endpoints: Change from baseline in fasting blood glucose, Change from baseline in HbA1c and 1 more. Started Oct 2017; status: recruiting.
02
Drugs
glutazumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12617000811303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000811303.